Currently, there are 44.21M common shares owned by the public and among those 37.43M shares have been available to trade.
The company’s stock has a 5-day price change of 6.73% and -75.03% over the past three months. HBIO shares are trading -83.31% year to date (YTD), with the 12-month market performance down to -90.43% lower. It has a 12-month low price of $0.29 and touched a high of $3.62 over the same period. HBIO has an average intraday trading volume of 352.10K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.05%, -31.57%, and -81.03% respectively.
Institutional ownership of Harvard Bioscience Inc (NASDAQ: HBIO) shares accounts for 65.42% of the company’s 44.21M shares outstanding.
It has a market capitalization of $15.57M and a beta (3y monthly) value of 1.46. The earnings-per-share (ttm) stands at -$1.32. Price movements for the stock have been influenced by the stock’s volatility, which stands at 30.61% over the week and 14.59% over the month.
Analysts forecast that Harvard Bioscience Inc (HBIO) will achieve an EPS of -0.03 for the current quarter, 0.03 for the next quarter and 0.05 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.03 while analysts give the company a high EPS estimate of -0.03. Comparatively, EPS for the current quarter was 0.0 a year ago.
The Benchmark Company coverage for the Harvard Bioscience Inc (HBIO) stock in a research note released on March 10, 2023 offered a Buy rating with a price target of $4. The Benchmark Company was of a view on January 07, 2021 that the stock is Buy, while Northland Capital gave the stock Outperform rating on December 09, 2020, issuing a price target of $6. KeyBanc Capital Markets on their part issued Overweight rating on November 10, 2020.
